Loading...
•
Dec 31, 2023
Editas Q4 2023 Earnings Report
Editas Medicine reported Q4 2023 results, highlighting progress in clinical trials and business development.
Key Takeaways
Editas Medicine reported a net loss of $18.9 million for Q4 2023, with collaboration revenue increasing significantly due to the Vertex license agreement. The company is focused on advancing its reni-cel program and expects its cash runway to extend into 2026.
Aligned with FDA that RUBY is a single Phase 1/2/3 trial.
Initiated enrollment in the adolescent cohort in the RUBY trial.
Entered into a license agreement with Vertex Pharmaceuticals for Cas9 gene editing technology.
Cash, cash equivalents, and marketable securities were $427.1 million as of December 31, 2023.
Editas
Editas
Editas Revenue by Segment
Revenue by Segment
Collab & R&D Rev Revenue
CapyFin.com Forward Guidance
Editas Medicine anticipates presenting additional clinical data from the RUBY and EdiTHAL trials in mid-2024 and further updates by year-end 2024. They also expect existing cash, cash equivalents, and marketable securities to fund operating expenses and capital expenditures into 2026.
Positive Outlook
- On track to present additional clinical data from the RUBY trial in mid-2024.
- On track to present additional clinical data from the EdiTHAL trial of reni-cel in mid-2024.
- Company aligned with FDA that RUBY is a single Phase 1/2/3 trial
- Initiated enrollment in the adolescent cohort in the RUBY trial
- Strong financial position with operational runway expected into 2026